



Implementation Advice: Proposed Scope

Therapeutic area: Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer



Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the *Canadian Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.



Background

On March 3, 2023, CADTH issued a [recommendation for reimbursement with clinical criteria and/or conditions](#) for Pluvicto (lutetium vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have received at least 1 androgen receptor pathway inhibitor and taxane-based chemotherapy. At the request of the drug programs that participate in the CADTH reimbursement review processes, CADTH is convening an implementation advice panel to advise the drug programs on radiopharmaceuticals that can be used to identify patients eligible for treatment with Pluvicto for prostate cancer. This document outlines a draft scope for the panel discussions, including which drugs are under consideration and questions to be addressed by the panel.

Consultation Process and Objectives

The implementation advice panel will comprise experts working in Canada in the area of nuclear medicine and theranostics. In addition to the clinical panellists and CADTH staff, representatives from public drug programs, the pan-Canadian Pharmaceutical Alliance, and the Canadian Association of Provincial Cancer Agencies may participate in the discussion and provide input in advance of the meeting on the topics for discussion. For more information on the implementation advice process, please refer to [CADTH Procedures for Medical Imaging Implementation Advice](#).

The CADTH Provincial Advisory Group and Formulary Working Group raised the following issues to be addressed by the implementation advice panel.

- In addition to gallium gozetotide, what other prostate-specific membrane antigen–PET radiopharmaceuticals could be used in clinical practice to identify patients who could be candidates for treatment with lutetium vipivotide tetraxetan?

Opportunities for Stakeholder Input

CADTH welcomes input from patient and clinician groups as well as manufacturers whose product(s) may be impacted by the implementation advice. Stakeholders are invited to provide comments and/or complementary information using the [comments on implementation advice request template](#). This input will be considered by CADTH and the implementation advice panel in their deliberations.

Opportunities for Feedback on Draft Advice

When ready, a draft of the implementation advice will be posted for stakeholder feedback on the CADTH website. Eligible stakeholders are welcome to provide feedback on the draft advice using the [CADTH Feedback on Draft Implementation Advice Report](#) template.

Drugs

Table 1: List of Drugs Under Consideration

Generic name (brand name)	Approval status and manufacturer	Indication(s)
Gallium Ga-68 gozetotide (Illuccix [kit for the preparation of gallium (⁶⁸ Ga) gozetotide injection])	Approved in Canada (2022), the US (2021), and Australia (2021). Telix Pharmaceuticals Limited (US) Isotope can be sourced from cyclotron or Ge-68 generator.	(Canada label, 10/2022) Illuccix [kit for the preparation of gallium (⁶⁸ Ga) gozetotide injection] is indicated for use with positron emission tomography (PET) of prostate specific membrane antigen (PSMA) positive lesions in men with prostate cancer: <ul style="list-style-type: none"> with suspected metastasis who are suitable for initial definitive therapy with suspected recurrence with elevated serum prostate specific antigen (PSA) level.
Gallium Ga-68 gozetotide (Locametz [kit for the preparation of gallium (⁶⁸ Ga) gozetotide injection])	Approved in Canada (2023), the US (2022), and the EU (2022). Novartis Pharmaceuticals Isotope can be sourced from cyclotron or Ge-68 generator.	(Canada label, 4/2023) Locametz [kit for the preparation of gallium (⁶⁸ Ga) gozetotide injection], after radiolabeling with gallium-68, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: <ul style="list-style-type: none"> with suspected metastasis who are candidates for initial definitive therapy with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level for selection of patients with metastatic prostate cancer (mCRPC), for whom PSMA-directed therapy is indicated.
¹⁸ F PSMA-1007	Not currently approved as a commercial product in Canada. Licensed for development in Canada by CPDC from ABX GmbH, Germany. Isotope sourced from cyclotron.	In phase III development in Canada by CPDC. In use in Canadian clinical trials (NCT03525288 and NCT04557501) of clinical utility.
Fluorine ¹⁸ F piflufolastat (¹⁸ F-DCFPyL) (Pylarify)	Not currently approved in Canada. Approved in the US (2021). Lantheus Holdings, Inc. (Original approval given to Progenics Pharmaceuticals) Isotope sourced from cyclotron.	(US label, 5/2021) Pylarify is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: <ul style="list-style-type: none"> with suspected metastasis who are candidates for initial definitive therapy with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level Listed as investigational by CPDC. In use in Canadian registries (PREP registry, Ontario NCT03718260) and clinical trials (NCT03525288 and NCT04557501) of clinical utility.

¹⁸F PSMA-1007 = fluorine-18 prostate-specific membrane antigen; ¹⁸F-DCFPyL = fluorine-18 piflufolastat; ⁶⁸Ga PSMA-11 = gallium gozetotide; CPDC = Centre for Probe Development and Commercialization; EU = European Union; PREP = PSMA-PET for recurrent prostate cancer; PSMA = prostate-specific membrane antigen.